NASDAQ:DARE Dare Bioscience (DARE) Stock Price, News & Analysis $2.17 -0.69 (-24.13%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$2.15 -0.02 (-0.88%) As of 05/15/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dare Bioscience Stock (NASDAQ:DARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dare Bioscience alerts:Sign Up Key Stats Today's Range$2.05▼$2.3350-Day Range$1.30▼$3.2752-Week Range$1.27▼$9.19Volume1.22 million shsAverage Volume1.38 million shsMarket Capitalization$31.60 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use. In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market. Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.AI Generated. May Contain Errors. Read More Dare Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreDARE MarketRank™: Dare Bioscience scored higher than 44% of companies evaluated by MarketBeat, and ranked 656th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDare Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDare Bioscience has a consensus price target of $10.00, representing about 360.8% upside from its current price of $2.17.Amount of Analyst CoverageDare Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Dare Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dare Bioscience is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dare Bioscience is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDare Bioscience has a P/B Ratio of 10.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.56% of the float of Dare Bioscience has been sold short.Short Interest Ratio / Days to CoverDare Bioscience has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dare Bioscience has recently increased by 110.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDare Bioscience does not currently pay a dividend.Dividend GrowthDare Bioscience does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.47 News SentimentDare Bioscience has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Dare Bioscience this week, compared to 3 articles on an average week.Search Interest7 people have searched for DARE on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows4 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dare Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders4.10% of the stock of Dare Bioscience is held by insiders.Percentage Held by Institutions6.70% of the stock of Dare Bioscience is held by institutions.Read more about Dare Bioscience's insider trading history. Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dare Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DARE Stock News HeadlinesDaré Bioscience, Inc.: Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 15 at 10:16 AM | finanznachrichten.deDaré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in JuneMay 15 at 10:16 AM | msn.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 16 at 1:00 AM | Brownstone Research (Ad)Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...May 15 at 10:16 AM | finance.yahoo.comDaré Bioscience, Inc. (DARE) Q1 2026 Earnings Call TranscriptMay 14 at 10:01 PM | seekingalpha.comDaré Bioscience Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14 at 4:01 PM | globenewswire.comDare Bioscience (NASDAQ:DARE) Share Price Passes Above 50-Day Moving Average - What's Next?May 13 at 5:07 AM | americanbankingnews.comPositive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free ContraceptiveMay 12, 2026 | globenewswire.comSee More Headlines DARE Stock Analysis - Frequently Asked Questions How have DARE shares performed this year? Dare Bioscience's stock was trading at $1.93 at the start of the year. Since then, DARE shares have increased by 12.4% and is now trading at $2.17. How were Dare Bioscience's earnings last quarter? Dare Bioscience, Inc. (NASDAQ:DARE) announced its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.13. The biotechnology company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.03 million. Read the conference call transcript. When did Dare Bioscience's stock split? Shares of Dare Bioscience reverse split on the morning of Monday, July 1st 2024.The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Dare Bioscience IPO? Dare Bioscience (DARE) raised $102 million in an IPO on Thursday, April 10th 2014. The company issued 8,500,000 shares at $11.00-$13.00 per share. How do I buy shares of Dare Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dare Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dare Bioscience investors own include FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/14/2026Today5/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 DARE's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DARE CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees30Year Founded2006Price Target and Rating Average Price Target for Dare Bioscience$10.00 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+360.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.40 million Net MarginsN/A Pretax Margin-1,300.87% Return on EquityN/A Return on Assets-47.32% Debt Debt-to-Equity RatioN/A Current Ratio1.14 Quick Ratio1.14 Sales & Book Value Annual Sales$1.03 million Price / Sales30.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book10.85Miscellaneous Outstanding Shares14,560,000Free Float13,963,000Market Cap$31.60 million OptionableNot Optionable Beta1.09 Social Links 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:DARE) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrading legend: “I made millions for CEO clients just repeating this 1 secret”TradeSmith Senior Analyst Jeff Clark has guided readers through 300-plus winning trades over 9 years - across ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
